SlideShare ist ein Scribd-Unternehmen logo
1 von 33
ANTIDEPRESSANTS
Phani.karnati
DEPRESSION
 Types
 Symptoms

 Diagnosis

 Causes

 Treatment
TYPES OF DEPRESSION
           Major depression
           Chronic depression (Dysthymia)

           Atypical depression

           Bipolar disorder/Manic depression

           Seasonal depression (SAD)
SYMPTOMS
   persistently sad, anxious, or empty moods
   loss of pleasure in usual activities (anhedonia)
   feelings of helplessness, guilt, or worthlessness
   crying, hopelessness, or persistent pessimism
   fatigue or decreased energy
   loss of memory, concentration, or decision-making capability
   restlessness, irritability
   sleep disturbances
   change in appetite or weight
   physical symptoms that defy diagnosis and do not respond to
    treatment (especially pain and gastrointestinal complaints)
   thoughts of suicide or death, or suicide attempts
   poor self-image or self-esteem (as illustrated, for example, by
    verbal self-reproach)
DIAGNOSIS
 Extensive patient and family history
 Blood test for hypothyroidism

 Current medication

 DSM-IV
     One  of the first two symptoms
     Five other symptoms
CAUSES OF DEPRESSION
 Genetics
 Death/Abuse

 Medications
TREATMENT FOR DEPRESSION
 Psychotherapy
 Electroconvulsive therapy

 Natural alternatives

 Medication
      SSRIs
      MAOIs

      TCAs

      SNRIs

      NDRIs

      TeCAs
NEUROTRANSMITTERS AND THE
CATECHOLAMINE HYPOTHESIS
 Neurotransmitters pass along signal
 Smaller amount of neurotransmitters causes
  depression
MONOAMINE OXIDASE (MAO) AND
DEPRESSION
   MAO catalyze deamination of intracellular
    monoamines
     MAO-A   oxidizes epinephrine, norepinephrine,
      serotonin
     MAO-B oxidizes phenylethylamine
     Both oxidize dopamine nonpreferentially
   MAO transporters reuptake extracellular
    monoamine
MONOAMINE OXIDASE INHIBITORS
(MAOIS)
   History
     Isoniazid
     Iproniazid
 Current Drugs
 Mechanism of Action

 Side Effects          Isoniazid




                        Iproniazid
MAOIS ON THE MARKET
   MAO Inhibitors (nonselective)
     Phenelzine (Nardil)
     Tranylcypromine (Parnate)
     Isocarboxazid (Marplan)
   MAO-B Inhibitors (selective for MAO-B)
     Selegiline   (Emsam)
MAOIS MECHANISM OF ACTION
 MAO contains a
  cysteinyl-linked
  flavin
 MAOIs covalently
  bind to N-5 of the
  flavin residue of
  the enzyme
MAOIS SIDE EFFECTS
MAOIS SIDE EFFECTS
 Side effects have put MAOIs in the second or
  third line of defense despite superior efficacy
 MAO-A inhibitors interfere with breakdown of
  tyramine
     High tyramine levels cause hypertensive crisis (the
      “cheese effect”)
     Can be controlled with restricted diet
   MAOIs interact with certain drugs
     Serotoninsyndrome (muscle rigidity, fever, seizures)
     Pain medications and SSRIs must be avoided
THE RECEPTOR SENSITIVITY
HYPOTHESIS
 Supersensitivity and up-regulation of post-
  synaptic receptors leads to depression
 Suicidal and depressed patients have increased
  5HT-α2 receptors
TRICYCLIC ANTIDEPRESSANTS
(TCAS)
   History
     Imipramine
 Current Drugs
 Mechanism of Action

 Side Effects




                        Imipramine
TCAS ON THE MARKET
 Amitriptyline
 Desipramine (Norpramin)

 Doxepin (Sinequan)

 Imipramine (Tofranil, Tofranil-PM)

 Nortriptyline (Pamelor)

 Protriptyline (Vivactil)

 Trimipramine (Surmontil)
TCAS MECHANISM OF ACTION
 TCAs inhibit serotonin,
  norepinephrine, and dopamine
  transporters, slowing reuptake
 TCAs also allow for the
  downregulation of post-
  synaptic receptors
 All TCAs and SSRIs contain
  an essential amino group that
  appears to interact with Asp-
  98 in hSERT
TCAS SIDE EFFECTS
   Muscarinic M1 receptor antagonism - anticholinergic
    effects including dry mouth, blurred vision,
    constipation, urinary retention and impotence
   Histamine H1 receptor antagonism - sedation and
    weight gain
   Adrenergic α receptor antagonism - postural
    hypotension
   Direct membrane effects - reduced seizure threshold,
    arrhythmia
   Serotonin 5-HT2 receptor antagonism - weight gain
    (and reduced anxiety)
TCAS SIDE EFFECTS
 Nonselectivity results in
  greater side effects
 TCAs can also lead to
  cardiotoxicity
     Increased LDH leakage
     Slow cardiac conduction
   High potency can lead to
    mania
     Contraindicated with
      persons with bipolar
      disorder or manic depression
TETRACYCLIC ANTIDEPRESSANTS
(TECAS)
   Current Drugs
     Mirtazapine   (Remeron)
   Mechanism of Action
     Same   as TCAs
   Side Effects
SELECTIVE SEROTONIN REUPTAKE
INHIBITORS
 Most commonly prescribed class
 Current drugs

 Mechanism of action

 Side effects




                                   Serotonin
SSRIS ON THE MARKET
 citalopram (Celexa)
 dapoxetine (Priligy)

 escitalopram (Lexapro)

 fluoxetine (Prozac)

 fluvoxamine (Luvox)                  Fluoxetine 1:1

 paroxetine (Paxil)

 sertraline (Zoloft)

 zimelidine (Zelmid) (discontinued)

 indalpine (Upstene) (discontinued)


                                          Sertraline
SSRIS MECHANISM OF ACTION
 Exact mechanism remains uncertain
 Ser-438 residue in the human serotonin
  transporter (hSERT) appears to be a determining
  factor in SSRI potency
 Antidepressants interact directly with hSERT

 http://www.mayoclinic.com/health/antidepressants/MM0066
SSRIS SIDE EFFECTS
SSRIS SIDE EFFECTS
 Many disappear within 4 weeks (adaption phase)
 Side effects more manageable compared to
  MAOIs and TCAs
 Sexual side effects are common

 SSRI cessation syndrome
     Brainzaps
     Sexual dysfunction
SEROTONIN-NOREPINEPHRINE
REUPTAKE INHIBITORS (SNRIS)
 Slightly greater efficacy than SSRIs
 Slightly fewer adverse effects than SSRIs

 Current drugs
     Venlafaxine (Effexor)
     Duloxetine (Cymbalta)
   Mechanism of Action
     Verysimilar to SSRIs
     Works on both neurotransmitters
                                        Venlafaxine 1:1
   Side effects                        Duloxetine
     Similar   to SSRIs
     Suicide
NOREPINEPHRINE-DOPAMINE
REUPTAKE INHIBITORS (NDRIS)
   Current drugs
     Bupropion    (Wellbutrin)
   Mechanims of Action
     Similar to SSRIs and SNRIs
     More potent in inhibiting dopamine
     Also anα3-β4 nicotinic antagonist
                                               Bupropion 1:1
   Adverse effects
     Lowers    seizure threshold
     Suicide
     Does not cause weight gain or sexual dysfunction
      (even used to treat the two)
ASSIGNED READING
 An Introduction to Medicinal Chemistry, by
  Graham L. Patrick, Chapter 20, pp. 593-8.
 Kelly, John. Novel therapeutic targets for the
  treatment of depression. Current Medicinal
  Chemistry: Central Nervous System Agents
  (2003), 3(4), 311-322.

Optional Reading:

Wong, David T.; Perry, Kenneth W.; Bymaster, Frank P. Case
History: The Discovery of Fluoxetine Hydrochloride (Prozac).
Nature Reviews Drug Discovery (2005), 4(9), 764-774.

Krishnan, K. Ranga. Revisiting monoamine oxidase inhibitors.
Journal of Clinical Psychiatry (Memphis, TN, United States)
(2007), 68(Suppl. 8), 35-41.
HOMEWORK QUESTIONS
1.   Many of the medications to treat depression are thought to involve
     systems utilizing the monoamine neurotransmitters, noradrenaline,
     dopamine, and serotonin (5-HT). Draw the structures of these
     neurotransmitters. Why are they called monoamines? Illustrate their
     structural resemblance to one another.
2.   Monoamine oxidase inhibitors (MAOIs) increase CNS synaptic
     concentrations of these monoamines by inhibiting an enzyme responsible
     for their degradation. Draw the reaction scheme for the biological
     degradation of noradrenaline by monoamine oxidase.
3.   Illustrate how the TCAs and SSRIs might resemble the monoamine
     neurotransmitters, providing one example of each class of antidepressant.
REFERENCES
   http://ajp.psychiatryonline.org/cgi/reprint/157/11/1901
   http://www.webmd.com/depression/
   http://pn.psychiatryonline.org/content/41/24/21.full
   http://www.mayoclinic.com/health/maois/MH00072
   http://www.springerlink.com/content/b9b8668ff59f89d7/fulltext.pdf
   http://www.emsam.com/pi_emsam.pdf
   http://www.nevdgp.org.au/info/topics/depression_theory.htm
   http://www.uspharmacist.com/content/t/psychotropic_disorders/c/11467/
   http://www.jbc.org/content/284/15/10276.full.pdf+html
   http://www.aafp.org/afp/981200ap/cadieux.html
   http://www.mayoclinic.com/health/antidepressants/MH00071
   http://books.google.com/books?
    id=R0W1ErpsQpkC&pg=PA565&lpg=PA565&dq=tcas+mechanism+of+action&source=bl&ots=oAS
    le2Z-
    pr&sig=36CB_3JY4uD3LIYvqXWmAb3nliY&hl=en&ei=HzfFS9OrB4Tu9gTD6_ixDg&sa=X&oi=bo
    ok_result&ct=result&resnum=8&ved=0CCoQ6AEwBw#v=onepage&q=tcas%20mechanism%20of
    %20action&f=false
   http://www.informaworld.com/smpp/content~content=a916036122&db=all

Weitere ähnliche Inhalte

Was ist angesagt?

Antidepressant drugs
Antidepressant drugsAntidepressant drugs
Antidepressant drugsAmira Badr
 
Antidepressants -pharmacology
Antidepressants -pharmacologyAntidepressants -pharmacology
Antidepressants -pharmacologypavithra vinayak
 
Pharmacology of Antiepileptic Drugs
Pharmacology of Antiepileptic DrugsPharmacology of Antiepileptic Drugs
Pharmacology of Antiepileptic Drugsshabeel pn
 
Clinical pharmacology of antipsychotic agents
Clinical pharmacology of antipsychotic agentsClinical pharmacology of antipsychotic agents
Clinical pharmacology of antipsychotic agentsDomina Petric
 
Schizophrenia and Antipsychotic Drugs
Schizophrenia and Antipsychotic DrugsSchizophrenia and Antipsychotic Drugs
Schizophrenia and Antipsychotic DrugsFarazaJaved
 
Antidepressants
AntidepressantsAntidepressants
AntidepressantsKarthiga M
 
Antipsychotics and updates
Antipsychotics and updatesAntipsychotics and updates
Antipsychotics and updatesJyoti Sharma
 
Drug used in Parkinson,Alzheimer and CNS stimulants
Drug used in Parkinson,Alzheimer and CNS stimulantsDrug used in Parkinson,Alzheimer and CNS stimulants
Drug used in Parkinson,Alzheimer and CNS stimulantsRajkumar Kumawat
 
Drug treatment of alzheimers disease
Drug treatment of alzheimers diseaseDrug treatment of alzheimers disease
Drug treatment of alzheimers diseaseNaser Tadvi
 
Anti psychotics & anti manic drugs
Anti psychotics & anti manic drugsAnti psychotics & anti manic drugs
Anti psychotics & anti manic drugsDr Resu Neha Reddy
 
Classification of Antidepressants & “Diagnosis & Pathophysiology of Depression”
Classification of Antidepressants & “Diagnosis & Pathophysiology of Depression”Classification of Antidepressants & “Diagnosis & Pathophysiology of Depression”
Classification of Antidepressants & “Diagnosis & Pathophysiology of Depression”Sawsan Aboul-Fotouh
 
Pharmacotherapy of depression
Pharmacotherapy of depressionPharmacotherapy of depression
Pharmacotherapy of depressionMANISH mohan
 

Was ist angesagt? (20)

Antidepressant drugs
Antidepressant drugsAntidepressant drugs
Antidepressant drugs
 
Antidepressants Pharmacology
Antidepressants  PharmacologyAntidepressants  Pharmacology
Antidepressants Pharmacology
 
Antidepressants -pharmacology
Antidepressants -pharmacologyAntidepressants -pharmacology
Antidepressants -pharmacology
 
Pharmacology of Antiepileptic Drugs
Pharmacology of Antiepileptic DrugsPharmacology of Antiepileptic Drugs
Pharmacology of Antiepileptic Drugs
 
Antidepressants
AntidepressantsAntidepressants
Antidepressants
 
Anti-Depressant
Anti-Depressant Anti-Depressant
Anti-Depressant
 
ANTIDEPRESSANTS
ANTIDEPRESSANTSANTIDEPRESSANTS
ANTIDEPRESSANTS
 
Clinical pharmacology of antipsychotic agents
Clinical pharmacology of antipsychotic agentsClinical pharmacology of antipsychotic agents
Clinical pharmacology of antipsychotic agents
 
Schizophrenia and Antipsychotic Drugs
Schizophrenia and Antipsychotic DrugsSchizophrenia and Antipsychotic Drugs
Schizophrenia and Antipsychotic Drugs
 
Antidepressants
AntidepressantsAntidepressants
Antidepressants
 
Antipsychotics and updates
Antipsychotics and updatesAntipsychotics and updates
Antipsychotics and updates
 
Drug used in Parkinson,Alzheimer and CNS stimulants
Drug used in Parkinson,Alzheimer and CNS stimulantsDrug used in Parkinson,Alzheimer and CNS stimulants
Drug used in Parkinson,Alzheimer and CNS stimulants
 
Drug treatment of alzheimers disease
Drug treatment of alzheimers diseaseDrug treatment of alzheimers disease
Drug treatment of alzheimers disease
 
Anti psychotics & anti manic drugs
Anti psychotics & anti manic drugsAnti psychotics & anti manic drugs
Anti psychotics & anti manic drugs
 
Antidepressants
AntidepressantsAntidepressants
Antidepressants
 
Classification of Antidepressants & “Diagnosis & Pathophysiology of Depression”
Classification of Antidepressants & “Diagnosis & Pathophysiology of Depression”Classification of Antidepressants & “Diagnosis & Pathophysiology of Depression”
Classification of Antidepressants & “Diagnosis & Pathophysiology of Depression”
 
Pharmacotherapy of depression
Pharmacotherapy of depressionPharmacotherapy of depression
Pharmacotherapy of depression
 
ANTIDEPRESSANTS
ANTIDEPRESSANTSANTIDEPRESSANTS
ANTIDEPRESSANTS
 
Antidepressant drugs
Antidepressant drugsAntidepressant drugs
Antidepressant drugs
 
Antidepressants
AntidepressantsAntidepressants
Antidepressants
 

Andere mochten auch (20)

Antidepressants powerpoint
Antidepressants powerpointAntidepressants powerpoint
Antidepressants powerpoint
 
Anti depressants
Anti depressants Anti depressants
Anti depressants
 
Antidepressants
AntidepressantsAntidepressants
Antidepressants
 
Anti depressants
Anti depressantsAnti depressants
Anti depressants
 
Anti depressant and its classifications
Anti depressant and its classificationsAnti depressant and its classifications
Anti depressant and its classifications
 
Post stroke psychiatric symptoms
Post stroke psychiatric symptomsPost stroke psychiatric symptoms
Post stroke psychiatric symptoms
 
Antidepressants
Antidepressants Antidepressants
Antidepressants
 
Parkinsonism
ParkinsonismParkinsonism
Parkinsonism
 
Antidepressents Med Chem Lecture
Antidepressents Med Chem LectureAntidepressents Med Chem Lecture
Antidepressents Med Chem Lecture
 
Antipsychotics Med chem lecture
Antipsychotics Med chem lecture Antipsychotics Med chem lecture
Antipsychotics Med chem lecture
 
SEROTONIN (VK)
SEROTONIN (VK)SEROTONIN (VK)
SEROTONIN (VK)
 
Neurologist approach to depression
Neurologist approach to depressionNeurologist approach to depression
Neurologist approach to depression
 
Personality disorder epidemiology & etiology
Personality disorder  epidemiology & etiologyPersonality disorder  epidemiology & etiology
Personality disorder epidemiology & etiology
 
TCAS
TCASTCAS
TCAS
 
Biotechnology Notes
Biotechnology NotesBiotechnology Notes
Biotechnology Notes
 
Seminar On Antidepressants
Seminar On AntidepressantsSeminar On Antidepressants
Seminar On Antidepressants
 
Parkinson disease by Petar Jesic
Parkinson disease by Petar JesicParkinson disease by Petar Jesic
Parkinson disease by Petar Jesic
 
Tuberculosis
TuberculosisTuberculosis
Tuberculosis
 
Antidepressant drugs
Antidepressant drugsAntidepressant drugs
Antidepressant drugs
 
Anti cholinergics-1, aimst
Anti cholinergics-1, aimstAnti cholinergics-1, aimst
Anti cholinergics-1, aimst
 

Ähnlich wie Antidepressants

Antidepressants.ppt
Antidepressants.pptAntidepressants.ppt
Antidepressants.pptImtiyaz60
 
Antidepressants.ppt
Antidepressants.pptAntidepressants.ppt
Antidepressants.pptImtiyaz60
 
Antidepressant drugs
Antidepressant drugsAntidepressant drugs
Antidepressant drugsAmira Badr
 
antidepressantS-THAMIZH.ppt
antidepressantS-THAMIZH.pptantidepressantS-THAMIZH.ppt
antidepressantS-THAMIZH.pptThamizh Arasan
 
Antidepressant_Pharmacology.ppt
Antidepressant_Pharmacology.pptAntidepressant_Pharmacology.ppt
Antidepressant_Pharmacology.pptAmanDeepTiwari4
 
Antidepressant_Pharmacology.ppt
Antidepressant_Pharmacology.pptAntidepressant_Pharmacology.ppt
Antidepressant_Pharmacology.pptssuserc71950
 
Antidepressant_Pharmacology.ppt
Antidepressant_Pharmacology.pptAntidepressant_Pharmacology.ppt
Antidepressant_Pharmacology.pptImtiyaz60
 
Antidepressant_Pharmacology.ppt
Antidepressant_Pharmacology.pptAntidepressant_Pharmacology.ppt
Antidepressant_Pharmacology.pptprince1123
 
Anti depressants
Anti depressantsAnti depressants
Anti depressantsraj kumar
 
Anti depressant , antidepressant
Anti depressant , antidepressantAnti depressant , antidepressant
Anti depressant , antidepressantRavish Yadav
 
Palazidou 03
Palazidou 03Palazidou 03
Palazidou 03henkpar
 
Antidepressants. Mood Stabilizers. Psychostimulants
Antidepressants. Mood Stabilizers. PsychostimulantsAntidepressants. Mood Stabilizers. Psychostimulants
Antidepressants. Mood Stabilizers. PsychostimulantsEneutron
 
06 Psychotherapeutic Agents Upd
06 Psychotherapeutic Agents Upd06 Psychotherapeutic Agents Upd
06 Psychotherapeutic Agents UpdNurse Uragon
 
Updates on antidepressant medications
Updates on antidepressant medicationsUpdates on antidepressant medications
Updates on antidepressant medicationsBEDEER ELSHERBINY
 

Ähnlich wie Antidepressants (20)

Αντικαταθλιπτικα
ΑντικαταθλιπτικαΑντικαταθλιπτικα
Αντικαταθλιπτικα
 
Antidepressants.ppt
Antidepressants.pptAntidepressants.ppt
Antidepressants.ppt
 
Antidepressants.ppt
Antidepressants.pptAntidepressants.ppt
Antidepressants.ppt
 
New Antidepressant Dr.Rahul.pptx
New Antidepressant Dr.Rahul.pptxNew Antidepressant Dr.Rahul.pptx
New Antidepressant Dr.Rahul.pptx
 
Antidepressant drugs
Antidepressant drugsAntidepressant drugs
Antidepressant drugs
 
antidepressantS-THAMIZH.ppt
antidepressantS-THAMIZH.pptantidepressantS-THAMIZH.ppt
antidepressantS-THAMIZH.ppt
 
Antidepressant_Pharmacology.ppt
Antidepressant_Pharmacology.pptAntidepressant_Pharmacology.ppt
Antidepressant_Pharmacology.ppt
 
Antidepressant_Pharmacology.ppt
Antidepressant_Pharmacology.pptAntidepressant_Pharmacology.ppt
Antidepressant_Pharmacology.ppt
 
Antidepressant_Pharmacology.ppt
Antidepressant_Pharmacology.pptAntidepressant_Pharmacology.ppt
Antidepressant_Pharmacology.ppt
 
Antidepressant_Pharmacology.ppt
Antidepressant_Pharmacology.pptAntidepressant_Pharmacology.ppt
Antidepressant_Pharmacology.ppt
 
Anti depressants
Anti depressantsAnti depressants
Anti depressants
 
Anti depressants
Anti depressantsAnti depressants
Anti depressants
 
Anti depressant , antidepressant
Anti depressant , antidepressantAnti depressant , antidepressant
Anti depressant , antidepressant
 
phants
phantsphants
phants
 
Palazidou 03
Palazidou 03Palazidou 03
Palazidou 03
 
Antidepressant
AntidepressantAntidepressant
Antidepressant
 
Antidepressants. Mood Stabilizers. Psychostimulants
Antidepressants. Mood Stabilizers. PsychostimulantsAntidepressants. Mood Stabilizers. Psychostimulants
Antidepressants. Mood Stabilizers. Psychostimulants
 
Stimulants
Stimulants Stimulants
Stimulants
 
06 Psychotherapeutic Agents Upd
06 Psychotherapeutic Agents Upd06 Psychotherapeutic Agents Upd
06 Psychotherapeutic Agents Upd
 
Updates on antidepressant medications
Updates on antidepressant medicationsUpdates on antidepressant medications
Updates on antidepressant medications
 

Kürzlich hochgeladen

Concurrency Control in Database Management system
Concurrency Control in Database Management systemConcurrency Control in Database Management system
Concurrency Control in Database Management systemChristalin Nelson
 
Expanded definition: technical and operational
Expanded definition: technical and operationalExpanded definition: technical and operational
Expanded definition: technical and operationalssuser3e220a
 
MULTIDISCIPLINRY NATURE OF THE ENVIRONMENTAL STUDIES.pptx
MULTIDISCIPLINRY NATURE OF THE ENVIRONMENTAL STUDIES.pptxMULTIDISCIPLINRY NATURE OF THE ENVIRONMENTAL STUDIES.pptx
MULTIDISCIPLINRY NATURE OF THE ENVIRONMENTAL STUDIES.pptxAnupkumar Sharma
 
Measures of Position DECILES for ungrouped data
Measures of Position DECILES for ungrouped dataMeasures of Position DECILES for ungrouped data
Measures of Position DECILES for ungrouped dataBabyAnnMotar
 
EMBODO Lesson Plan Grade 9 Law of Sines.docx
EMBODO Lesson Plan Grade 9 Law of Sines.docxEMBODO Lesson Plan Grade 9 Law of Sines.docx
EMBODO Lesson Plan Grade 9 Law of Sines.docxElton John Embodo
 
4.16.24 Poverty and Precarity--Desmond.pptx
4.16.24 Poverty and Precarity--Desmond.pptx4.16.24 Poverty and Precarity--Desmond.pptx
4.16.24 Poverty and Precarity--Desmond.pptxmary850239
 
Field Attribute Index Feature in Odoo 17
Field Attribute Index Feature in Odoo 17Field Attribute Index Feature in Odoo 17
Field Attribute Index Feature in Odoo 17Celine George
 
Integumentary System SMP B. Pharm Sem I.ppt
Integumentary System SMP B. Pharm Sem I.pptIntegumentary System SMP B. Pharm Sem I.ppt
Integumentary System SMP B. Pharm Sem I.pptshraddhaparab530
 
Incoming and Outgoing Shipments in 3 STEPS Using Odoo 17
Incoming and Outgoing Shipments in 3 STEPS Using Odoo 17Incoming and Outgoing Shipments in 3 STEPS Using Odoo 17
Incoming and Outgoing Shipments in 3 STEPS Using Odoo 17Celine George
 
The Contemporary World: The Globalization of World Politics
The Contemporary World: The Globalization of World PoliticsThe Contemporary World: The Globalization of World Politics
The Contemporary World: The Globalization of World PoliticsRommel Regala
 
HỌC TỐT TIẾNG ANH 11 THEO CHƯƠNG TRÌNH GLOBAL SUCCESS ĐÁP ÁN CHI TIẾT - CẢ NĂ...
HỌC TỐT TIẾNG ANH 11 THEO CHƯƠNG TRÌNH GLOBAL SUCCESS ĐÁP ÁN CHI TIẾT - CẢ NĂ...HỌC TỐT TIẾNG ANH 11 THEO CHƯƠNG TRÌNH GLOBAL SUCCESS ĐÁP ÁN CHI TIẾT - CẢ NĂ...
HỌC TỐT TIẾNG ANH 11 THEO CHƯƠNG TRÌNH GLOBAL SUCCESS ĐÁP ÁN CHI TIẾT - CẢ NĂ...Nguyen Thanh Tu Collection
 
4.18.24 Movement Legacies, Reflection, and Review.pptx
4.18.24 Movement Legacies, Reflection, and Review.pptx4.18.24 Movement Legacies, Reflection, and Review.pptx
4.18.24 Movement Legacies, Reflection, and Review.pptxmary850239
 
4.16.24 21st Century Movements for Black Lives.pptx
4.16.24 21st Century Movements for Black Lives.pptx4.16.24 21st Century Movements for Black Lives.pptx
4.16.24 21st Century Movements for Black Lives.pptxmary850239
 
Keynote by Prof. Wurzer at Nordex about IP-design
Keynote by Prof. Wurzer at Nordex about IP-designKeynote by Prof. Wurzer at Nordex about IP-design
Keynote by Prof. Wurzer at Nordex about IP-designMIPLM
 
Daily Lesson Plan in Mathematics Quarter 4
Daily Lesson Plan in Mathematics Quarter 4Daily Lesson Plan in Mathematics Quarter 4
Daily Lesson Plan in Mathematics Quarter 4JOYLYNSAMANIEGO
 
Grade 9 Quarter 4 Dll Grade 9 Quarter 4 DLL.pdf
Grade 9 Quarter 4 Dll Grade 9 Quarter 4 DLL.pdfGrade 9 Quarter 4 Dll Grade 9 Quarter 4 DLL.pdf
Grade 9 Quarter 4 Dll Grade 9 Quarter 4 DLL.pdfJemuel Francisco
 
Active Learning Strategies (in short ALS).pdf
Active Learning Strategies (in short ALS).pdfActive Learning Strategies (in short ALS).pdf
Active Learning Strategies (in short ALS).pdfPatidar M
 
TEACHER REFLECTION FORM (NEW SET........).docx
TEACHER REFLECTION FORM (NEW SET........).docxTEACHER REFLECTION FORM (NEW SET........).docx
TEACHER REFLECTION FORM (NEW SET........).docxruthvilladarez
 
INTRODUCTION TO CATHOLIC CHRISTOLOGY.pptx
INTRODUCTION TO CATHOLIC CHRISTOLOGY.pptxINTRODUCTION TO CATHOLIC CHRISTOLOGY.pptx
INTRODUCTION TO CATHOLIC CHRISTOLOGY.pptxHumphrey A Beña
 
How to Add Barcode on PDF Report in Odoo 17
How to Add Barcode on PDF Report in Odoo 17How to Add Barcode on PDF Report in Odoo 17
How to Add Barcode on PDF Report in Odoo 17Celine George
 

Kürzlich hochgeladen (20)

Concurrency Control in Database Management system
Concurrency Control in Database Management systemConcurrency Control in Database Management system
Concurrency Control in Database Management system
 
Expanded definition: technical and operational
Expanded definition: technical and operationalExpanded definition: technical and operational
Expanded definition: technical and operational
 
MULTIDISCIPLINRY NATURE OF THE ENVIRONMENTAL STUDIES.pptx
MULTIDISCIPLINRY NATURE OF THE ENVIRONMENTAL STUDIES.pptxMULTIDISCIPLINRY NATURE OF THE ENVIRONMENTAL STUDIES.pptx
MULTIDISCIPLINRY NATURE OF THE ENVIRONMENTAL STUDIES.pptx
 
Measures of Position DECILES for ungrouped data
Measures of Position DECILES for ungrouped dataMeasures of Position DECILES for ungrouped data
Measures of Position DECILES for ungrouped data
 
EMBODO Lesson Plan Grade 9 Law of Sines.docx
EMBODO Lesson Plan Grade 9 Law of Sines.docxEMBODO Lesson Plan Grade 9 Law of Sines.docx
EMBODO Lesson Plan Grade 9 Law of Sines.docx
 
4.16.24 Poverty and Precarity--Desmond.pptx
4.16.24 Poverty and Precarity--Desmond.pptx4.16.24 Poverty and Precarity--Desmond.pptx
4.16.24 Poverty and Precarity--Desmond.pptx
 
Field Attribute Index Feature in Odoo 17
Field Attribute Index Feature in Odoo 17Field Attribute Index Feature in Odoo 17
Field Attribute Index Feature in Odoo 17
 
Integumentary System SMP B. Pharm Sem I.ppt
Integumentary System SMP B. Pharm Sem I.pptIntegumentary System SMP B. Pharm Sem I.ppt
Integumentary System SMP B. Pharm Sem I.ppt
 
Incoming and Outgoing Shipments in 3 STEPS Using Odoo 17
Incoming and Outgoing Shipments in 3 STEPS Using Odoo 17Incoming and Outgoing Shipments in 3 STEPS Using Odoo 17
Incoming and Outgoing Shipments in 3 STEPS Using Odoo 17
 
The Contemporary World: The Globalization of World Politics
The Contemporary World: The Globalization of World PoliticsThe Contemporary World: The Globalization of World Politics
The Contemporary World: The Globalization of World Politics
 
HỌC TỐT TIẾNG ANH 11 THEO CHƯƠNG TRÌNH GLOBAL SUCCESS ĐÁP ÁN CHI TIẾT - CẢ NĂ...
HỌC TỐT TIẾNG ANH 11 THEO CHƯƠNG TRÌNH GLOBAL SUCCESS ĐÁP ÁN CHI TIẾT - CẢ NĂ...HỌC TỐT TIẾNG ANH 11 THEO CHƯƠNG TRÌNH GLOBAL SUCCESS ĐÁP ÁN CHI TIẾT - CẢ NĂ...
HỌC TỐT TIẾNG ANH 11 THEO CHƯƠNG TRÌNH GLOBAL SUCCESS ĐÁP ÁN CHI TIẾT - CẢ NĂ...
 
4.18.24 Movement Legacies, Reflection, and Review.pptx
4.18.24 Movement Legacies, Reflection, and Review.pptx4.18.24 Movement Legacies, Reflection, and Review.pptx
4.18.24 Movement Legacies, Reflection, and Review.pptx
 
4.16.24 21st Century Movements for Black Lives.pptx
4.16.24 21st Century Movements for Black Lives.pptx4.16.24 21st Century Movements for Black Lives.pptx
4.16.24 21st Century Movements for Black Lives.pptx
 
Keynote by Prof. Wurzer at Nordex about IP-design
Keynote by Prof. Wurzer at Nordex about IP-designKeynote by Prof. Wurzer at Nordex about IP-design
Keynote by Prof. Wurzer at Nordex about IP-design
 
Daily Lesson Plan in Mathematics Quarter 4
Daily Lesson Plan in Mathematics Quarter 4Daily Lesson Plan in Mathematics Quarter 4
Daily Lesson Plan in Mathematics Quarter 4
 
Grade 9 Quarter 4 Dll Grade 9 Quarter 4 DLL.pdf
Grade 9 Quarter 4 Dll Grade 9 Quarter 4 DLL.pdfGrade 9 Quarter 4 Dll Grade 9 Quarter 4 DLL.pdf
Grade 9 Quarter 4 Dll Grade 9 Quarter 4 DLL.pdf
 
Active Learning Strategies (in short ALS).pdf
Active Learning Strategies (in short ALS).pdfActive Learning Strategies (in short ALS).pdf
Active Learning Strategies (in short ALS).pdf
 
TEACHER REFLECTION FORM (NEW SET........).docx
TEACHER REFLECTION FORM (NEW SET........).docxTEACHER REFLECTION FORM (NEW SET........).docx
TEACHER REFLECTION FORM (NEW SET........).docx
 
INTRODUCTION TO CATHOLIC CHRISTOLOGY.pptx
INTRODUCTION TO CATHOLIC CHRISTOLOGY.pptxINTRODUCTION TO CATHOLIC CHRISTOLOGY.pptx
INTRODUCTION TO CATHOLIC CHRISTOLOGY.pptx
 
How to Add Barcode on PDF Report in Odoo 17
How to Add Barcode on PDF Report in Odoo 17How to Add Barcode on PDF Report in Odoo 17
How to Add Barcode on PDF Report in Odoo 17
 

Antidepressants

  • 2. DEPRESSION  Types  Symptoms  Diagnosis  Causes  Treatment
  • 3. TYPES OF DEPRESSION  Major depression  Chronic depression (Dysthymia)  Atypical depression  Bipolar disorder/Manic depression  Seasonal depression (SAD)
  • 4. SYMPTOMS  persistently sad, anxious, or empty moods  loss of pleasure in usual activities (anhedonia)  feelings of helplessness, guilt, or worthlessness  crying, hopelessness, or persistent pessimism  fatigue or decreased energy  loss of memory, concentration, or decision-making capability  restlessness, irritability  sleep disturbances  change in appetite or weight  physical symptoms that defy diagnosis and do not respond to treatment (especially pain and gastrointestinal complaints)  thoughts of suicide or death, or suicide attempts  poor self-image or self-esteem (as illustrated, for example, by verbal self-reproach)
  • 5. DIAGNOSIS  Extensive patient and family history  Blood test for hypothyroidism  Current medication  DSM-IV  One of the first two symptoms  Five other symptoms
  • 6. CAUSES OF DEPRESSION  Genetics  Death/Abuse  Medications
  • 7. TREATMENT FOR DEPRESSION  Psychotherapy  Electroconvulsive therapy  Natural alternatives  Medication  SSRIs  MAOIs  TCAs  SNRIs  NDRIs  TeCAs
  • 8. NEUROTRANSMITTERS AND THE CATECHOLAMINE HYPOTHESIS  Neurotransmitters pass along signal  Smaller amount of neurotransmitters causes depression
  • 9. MONOAMINE OXIDASE (MAO) AND DEPRESSION  MAO catalyze deamination of intracellular monoamines  MAO-A oxidizes epinephrine, norepinephrine, serotonin  MAO-B oxidizes phenylethylamine  Both oxidize dopamine nonpreferentially  MAO transporters reuptake extracellular monoamine
  • 10. MONOAMINE OXIDASE INHIBITORS (MAOIS)  History  Isoniazid  Iproniazid  Current Drugs  Mechanism of Action  Side Effects Isoniazid Iproniazid
  • 11. MAOIS ON THE MARKET  MAO Inhibitors (nonselective)  Phenelzine (Nardil)  Tranylcypromine (Parnate)  Isocarboxazid (Marplan)  MAO-B Inhibitors (selective for MAO-B)  Selegiline (Emsam)
  • 12. MAOIS MECHANISM OF ACTION  MAO contains a cysteinyl-linked flavin  MAOIs covalently bind to N-5 of the flavin residue of the enzyme
  • 13.
  • 15. MAOIS SIDE EFFECTS  Side effects have put MAOIs in the second or third line of defense despite superior efficacy  MAO-A inhibitors interfere with breakdown of tyramine  High tyramine levels cause hypertensive crisis (the “cheese effect”)  Can be controlled with restricted diet  MAOIs interact with certain drugs  Serotoninsyndrome (muscle rigidity, fever, seizures)  Pain medications and SSRIs must be avoided
  • 16. THE RECEPTOR SENSITIVITY HYPOTHESIS  Supersensitivity and up-regulation of post- synaptic receptors leads to depression  Suicidal and depressed patients have increased 5HT-α2 receptors
  • 17. TRICYCLIC ANTIDEPRESSANTS (TCAS)  History  Imipramine  Current Drugs  Mechanism of Action  Side Effects Imipramine
  • 18. TCAS ON THE MARKET  Amitriptyline  Desipramine (Norpramin)  Doxepin (Sinequan)  Imipramine (Tofranil, Tofranil-PM)  Nortriptyline (Pamelor)  Protriptyline (Vivactil)  Trimipramine (Surmontil)
  • 19. TCAS MECHANISM OF ACTION  TCAs inhibit serotonin, norepinephrine, and dopamine transporters, slowing reuptake  TCAs also allow for the downregulation of post- synaptic receptors  All TCAs and SSRIs contain an essential amino group that appears to interact with Asp- 98 in hSERT
  • 20. TCAS SIDE EFFECTS  Muscarinic M1 receptor antagonism - anticholinergic effects including dry mouth, blurred vision, constipation, urinary retention and impotence  Histamine H1 receptor antagonism - sedation and weight gain  Adrenergic α receptor antagonism - postural hypotension  Direct membrane effects - reduced seizure threshold, arrhythmia  Serotonin 5-HT2 receptor antagonism - weight gain (and reduced anxiety)
  • 21. TCAS SIDE EFFECTS  Nonselectivity results in greater side effects  TCAs can also lead to cardiotoxicity  Increased LDH leakage  Slow cardiac conduction  High potency can lead to mania  Contraindicated with persons with bipolar disorder or manic depression
  • 22. TETRACYCLIC ANTIDEPRESSANTS (TECAS)  Current Drugs  Mirtazapine (Remeron)  Mechanism of Action  Same as TCAs  Side Effects
  • 23. SELECTIVE SEROTONIN REUPTAKE INHIBITORS  Most commonly prescribed class  Current drugs  Mechanism of action  Side effects Serotonin
  • 24. SSRIS ON THE MARKET  citalopram (Celexa)  dapoxetine (Priligy)  escitalopram (Lexapro)  fluoxetine (Prozac)  fluvoxamine (Luvox) Fluoxetine 1:1  paroxetine (Paxil)  sertraline (Zoloft)  zimelidine (Zelmid) (discontinued)  indalpine (Upstene) (discontinued) Sertraline
  • 25. SSRIS MECHANISM OF ACTION  Exact mechanism remains uncertain  Ser-438 residue in the human serotonin transporter (hSERT) appears to be a determining factor in SSRI potency  Antidepressants interact directly with hSERT  http://www.mayoclinic.com/health/antidepressants/MM0066
  • 27. SSRIS SIDE EFFECTS  Many disappear within 4 weeks (adaption phase)  Side effects more manageable compared to MAOIs and TCAs  Sexual side effects are common  SSRI cessation syndrome  Brainzaps  Sexual dysfunction
  • 28. SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS)  Slightly greater efficacy than SSRIs  Slightly fewer adverse effects than SSRIs  Current drugs  Venlafaxine (Effexor)  Duloxetine (Cymbalta)  Mechanism of Action  Verysimilar to SSRIs  Works on both neurotransmitters Venlafaxine 1:1  Side effects Duloxetine  Similar to SSRIs  Suicide
  • 29.
  • 30. NOREPINEPHRINE-DOPAMINE REUPTAKE INHIBITORS (NDRIS)  Current drugs  Bupropion (Wellbutrin)  Mechanims of Action  Similar to SSRIs and SNRIs  More potent in inhibiting dopamine  Also anα3-β4 nicotinic antagonist Bupropion 1:1  Adverse effects  Lowers seizure threshold  Suicide  Does not cause weight gain or sexual dysfunction (even used to treat the two)
  • 31. ASSIGNED READING  An Introduction to Medicinal Chemistry, by Graham L. Patrick, Chapter 20, pp. 593-8.  Kelly, John. Novel therapeutic targets for the treatment of depression. Current Medicinal Chemistry: Central Nervous System Agents (2003), 3(4), 311-322. Optional Reading: Wong, David T.; Perry, Kenneth W.; Bymaster, Frank P. Case History: The Discovery of Fluoxetine Hydrochloride (Prozac). Nature Reviews Drug Discovery (2005), 4(9), 764-774. Krishnan, K. Ranga. Revisiting monoamine oxidase inhibitors. Journal of Clinical Psychiatry (Memphis, TN, United States) (2007), 68(Suppl. 8), 35-41.
  • 32. HOMEWORK QUESTIONS 1. Many of the medications to treat depression are thought to involve systems utilizing the monoamine neurotransmitters, noradrenaline, dopamine, and serotonin (5-HT). Draw the structures of these neurotransmitters. Why are they called monoamines? Illustrate their structural resemblance to one another. 2. Monoamine oxidase inhibitors (MAOIs) increase CNS synaptic concentrations of these monoamines by inhibiting an enzyme responsible for their degradation. Draw the reaction scheme for the biological degradation of noradrenaline by monoamine oxidase. 3. Illustrate how the TCAs and SSRIs might resemble the monoamine neurotransmitters, providing one example of each class of antidepressant.
  • 33. REFERENCES  http://ajp.psychiatryonline.org/cgi/reprint/157/11/1901  http://www.webmd.com/depression/  http://pn.psychiatryonline.org/content/41/24/21.full  http://www.mayoclinic.com/health/maois/MH00072  http://www.springerlink.com/content/b9b8668ff59f89d7/fulltext.pdf  http://www.emsam.com/pi_emsam.pdf  http://www.nevdgp.org.au/info/topics/depression_theory.htm  http://www.uspharmacist.com/content/t/psychotropic_disorders/c/11467/  http://www.jbc.org/content/284/15/10276.full.pdf+html  http://www.aafp.org/afp/981200ap/cadieux.html  http://www.mayoclinic.com/health/antidepressants/MH00071  http://books.google.com/books? id=R0W1ErpsQpkC&pg=PA565&lpg=PA565&dq=tcas+mechanism+of+action&source=bl&ots=oAS le2Z- pr&sig=36CB_3JY4uD3LIYvqXWmAb3nliY&hl=en&ei=HzfFS9OrB4Tu9gTD6_ixDg&sa=X&oi=bo ok_result&ct=result&resnum=8&ved=0CCoQ6AEwBw#v=onepage&q=tcas%20mechanism%20of %20action&f=false  http://www.informaworld.com/smpp/content~content=a916036122&db=all

Hinweis der Redaktion

  1. Major depression – recurring and disabling. Symptoms must last for at least two weeks and impair one’s ability to interfere with a person's ability to work, sleep, study, eat, and enjoy once-pleasurable activities. Chronic depression – less disabling than major depression, but symptoms can last longer, sometimes being unhappy for two years. More common in women, affects 10.9 million people. Atypical depression, rather than the other two, is characterized less by pervasive sadness and more by overeating, oversleeping, sensitivty to rejection Bipolar/manic depression oscillates between major depression and epsidoes of mania (extreme elation), Bipolar I – episode of mania with or without depression. Bipolar II – episode of depression with episode of hypomania or mania. Seasonal depression (SAD) – often occurs wehre winters are short or there is a big change in the amount of sunlgiht, and often treated with light therapy.
  2. MUST HAVE one of the top two AT LEAST five of the other symptoms Nearly DAILY For at least TWO WEEKS
  3. Doctor will ask many questions about personal mood, new behaviors, changes in routine Check blood and current drugs to rule out other factors (hypothyroidism, drug side effects) Drugs like antihypertensives, oral contraceptives, and Accutane for acne can cause depression BIG THING IS DISRUPTION IN FUNCTIONING
  4. Psycotherapy/talk therapy – especially useful when combined with meds. Goal is to teach good coping skills for every day stressors ECT – electric shock is applied to scalp through electrodes, results in seizure in the brain. Fast and effecitve in patients with depression or suicidal thoughts (good for suicide bc doesn’t have the same delayed onset as meds). Usually given up to three times a week for two to four weeks Natural alternatives – St. John’s wort (sold in teas and tablets, and in diet pills) not good for severe depression but can help mild depression
  5. SYNAPSE: Neurotransmitter passes along synapse from inside storage vesicles through transporters in the presynaptic cell to receptors in the post synaptic cell. Monoamine hypohtesis suggests that small amount of neurotransmitter causes depression
  6. Both early drugs developed in sixties for anti tuberculosis but found to have antidepressant effects, got off market due to toxicity
  7. Phenelzine – major depression Tranylcypromine – major depression Isocarboxazid – major depression Selegiline – comeback of MAOI (MAO-B inhibitor, more selective, loses selectivity at high doses) because no side effects from diet. Used primarily for treatment for Parkinson’s disease (also approved for major depression) – shows significant improvenemnt when taken with L-DOPA
  8. MAOIs bind to the N-5 of the flavin residue if MAO, which prevents MAO from catalyzing the oxidative deamination of the monoamine, increasing their intracellular concentration so more can be released.
  9. Bold ones are most common
  10. Major side effects have kept MAOI use limitied HUGE PITFALL IS DIETARY RESTRICTION Must avoid foods with high levels of tyramine like avocados, bananas, aged cheese, certain meats and wines This is however not seen with selegiline because that is a MAO-B inhibitor, and since tyramine displaces NOREPINEPHRINE from storage vesicles, it effects MAO-A more Serotonin syndrome is caused by drug interactions with herbal weight loss supplement (St John’s wort) and SSRIs and Pain meds like tramadol and meperidine
  11. Imipramine was first tried as an antipsychoti drug for schizophrenia, proved to be insufficient but proved to have antidepressant qualities, in the 50s around the same time as MAOIs. Imipramine is very good for severe depression, but it’s almost too good – also causes hypomania and mania
  12. Side effects have made them second line of defense to SSRIs but they are good for treatment resistant depression bc they are so strong. Amitriptyline – most widely used, most effectve Desipramine – active metabolite of imipramine, used for neuropathic pain Doxepin – used for depression and insomnia Imipramine – used for major depression and enuresis Nortriptyline – same thing Protriptyline – depression UNIQUE BECAUSE IT IS ENERGIZING rather than sedating Trimipramine – depression, insomnia, and pain
  13. Less selective in which cells they target, will prevent serotonin, norepinephrine, and dopamine reuptake
  14. Also first rationally designed drug class, up until the 70s the antidepressants were sort of found by accident Serotonin is also referred to as 5-hydroxytryptamine
  15. More trade names once patent is over but I kept original trade names Citalopram: Major depression Dapoxetine: Premature Ejaculation Escitalopram: Major depression and various other anxiety disorders Fluxoetine: Major depression, OCD, bulimia, etc Fluvoxamine: OCD Paroxetine: Major depression or anxiety Sertraline: Major depression or anxiety Zimelidine had neurological problems like Guillan Barre Indalpine had problems with fetal low WBC
  16. The drug binds in the residue to prevent the presynaptic serotonin transporter from reuptaking the serotonin neurotransmitter. This increases extracellular concentration of serotonin, allowing more messages to be passed along. Over time, this also leads to the downregulation of the postsynaptic receptors so they are fewer and less sensitive, so they more transmittance.
  17. Many side effects go away onec the body gets used to the drug because the drug takes sometime tos tart working Sexual side effects are common (ED, low libido) due to stimuatlion of 5-HT2 receptors leading to less release of dopamine
  18. Venlafaxine is a racemix mixture While SSRIs are less potent than the other classes of drugs, they have more manageable side effects so they’re considered better The mechanism is similar to SSRIs, as are the side effects. However, the rate of suicide for SNRIs has been debateable, especially venlafaxine. Finnish study showed Ven increased suicide risk 1.6 times compared to no treatment while Fluoxetine halved it. FDA study showed 5-fold increase in <25 so it is contraindicated in adolescents.
  19. Bupropion is a racemic mixture